[go: up one dir, main page]

DE69630145D1 - Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen - Google Patents

Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Info

Publication number
DE69630145D1
DE69630145D1 DE69630145T DE69630145T DE69630145D1 DE 69630145 D1 DE69630145 D1 DE 69630145D1 DE 69630145 T DE69630145 T DE 69630145T DE 69630145 T DE69630145 T DE 69630145T DE 69630145 D1 DE69630145 D1 DE 69630145D1
Authority
DE
Germany
Prior art keywords
taxal
derivatives
production
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630145T
Other languages
English (en)
Other versions
DE69630145T2 (de
Inventor
Herve Bouchard
Alain Commercon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of DE69630145D1 publication Critical patent/DE69630145D1/de
Publication of DE69630145T2 publication Critical patent/DE69630145T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69630145T 1995-12-22 1996-12-19 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen Expired - Lifetime DE69630145T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9515379 1995-12-22
FR9515379A FR2742751B1 (fr) 1995-12-22 1995-12-22 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/002031 WO1997023473A1 (fr) 1995-12-22 1996-12-19 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
DE69630145D1 true DE69630145D1 (de) 2003-10-30
DE69630145T2 DE69630145T2 (de) 2004-07-15

Family

ID=9485871

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630145T Expired - Lifetime DE69630145T2 (de) 1995-12-22 1996-12-19 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Country Status (40)

Country Link
US (1) US5728849A (de)
EP (1) EP0876362B1 (de)
JP (1) JP3953106B2 (de)
KR (1) KR100500351B1 (de)
CN (1) CN1103766C (de)
AR (1) AR005197A1 (de)
AT (1) ATE250593T1 (de)
AU (1) AU712597B2 (de)
BG (1) BG63204B1 (de)
BR (1) BR9612135A (de)
CA (1) CA2238884C (de)
CO (1) CO4520184A1 (de)
CZ (1) CZ294972B6 (de)
DE (1) DE69630145T2 (de)
DK (1) DK0876362T3 (de)
DZ (1) DZ2149A1 (de)
EA (1) EA001533B1 (de)
ES (1) ES2202490T3 (de)
FR (1) FR2742751B1 (de)
HU (1) HU225032B1 (de)
IL (1) IL124994A (de)
IN (4) IN186768B (de)
MA (1) MA26412A1 (de)
MX (1) MX9804688A (de)
MY (1) MY113934A (de)
NO (1) NO317358B1 (de)
NZ (1) NZ324337A (de)
OA (1) OA10700A (de)
PE (1) PE25198A1 (de)
PL (1) PL189311B1 (de)
PT (1) PT876362E (de)
RO (1) RO116194B1 (de)
SK (1) SK282835B6 (de)
TN (1) TNSN96169A1 (de)
TR (1) TR199801179T2 (de)
TW (1) TW371659B (de)
UA (1) UA48205C2 (de)
UY (1) UY24386A1 (de)
WO (1) WO1997023473A1 (de)
ZA (1) ZA9610737B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
PL350028A1 (en) 2000-02-02 2002-10-21 Univ Florida State Res Found C10 carbonate substituted taxanes as antitumor agents
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080107721A1 (en) * 2003-05-20 2008-05-08 Jonathan Lewis Combination Chemotherapy Comprising A Liposomal Platinum Complex
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1669358A1 (de) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxische Wirkstoffen auf Basis von neuen Taxanen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
FR3010839B1 (fr) * 2013-09-17 2017-04-21 Schneider Electric Ind Sas Dispositif de raccordement electrique d'au moins un conducteur dans une borne appartenant a un appareil electrique
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3319936B1 (de) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Brückenlinker zur konjugation von zellbindenden molekülen
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
KR20220147721A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017724C1 (ru) * 1990-07-12 1994-08-15 Дзе Юниверсити оф Канзас Способ получения производных таксола
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
JPH07505887A (ja) * 1992-04-17 1995-06-29 アボツト・ラボラトリーズ タキソール誘導体
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
MX9307777A (es) * 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.

Also Published As

Publication number Publication date
IN188469B (de) 2002-09-28
BR9612135A (pt) 1999-07-13
HU225032B1 (en) 2006-05-29
HK1017895A1 (en) 1999-12-03
FR2742751A1 (fr) 1997-06-27
MX9804688A (es) 1998-10-31
DK0876362T3 (da) 2004-02-02
BG102569A (en) 1999-04-30
JP2000502671A (ja) 2000-03-07
UY24386A1 (es) 2001-08-27
EA199800588A1 (ru) 1998-12-24
HUP9904046A1 (hu) 2001-04-28
FR2742751B1 (fr) 1998-01-30
MY113934A (en) 2002-06-29
TR199801179T2 (xx) 1998-10-21
BG63204B1 (bg) 2001-06-29
JP3953106B2 (ja) 2007-08-08
IL124994A (en) 2000-12-06
PL189311B1 (pl) 2005-07-29
PE25198A1 (es) 1998-05-10
HUP9904046A3 (en) 2001-08-28
IL124994A0 (en) 1999-01-26
IN188470B (de) 2002-09-28
AR005197A1 (es) 1999-04-14
PT876362E (pt) 2004-02-27
NO982580L (no) 1998-06-05
IN188680B (de) 2002-10-26
KR19990076680A (ko) 1999-10-15
SK282835B6 (sk) 2002-12-03
OA10700A (fr) 2002-11-27
KR100500351B1 (ko) 2005-12-21
EP0876362B1 (de) 2003-09-24
WO1997023473A1 (fr) 1997-07-03
CZ294972B6 (cs) 2005-04-13
US5728849A (en) 1998-03-17
NO982580D0 (no) 1998-06-05
NO317358B1 (no) 2004-10-18
DZ2149A1 (fr) 2002-10-23
EA001533B1 (ru) 2001-04-23
ZA9610737B (en) 1997-06-27
ATE250593T1 (de) 2003-10-15
TW371659B (en) 1999-10-11
MA26412A1 (fr) 2004-12-20
DE69630145T2 (de) 2004-07-15
RO116194B1 (ro) 2000-11-30
CN1103766C (zh) 2003-03-26
CN1205697A (zh) 1999-01-20
CA2238884A1 (fr) 1997-07-03
CA2238884C (fr) 2007-02-06
PL327405A1 (en) 1998-12-07
ES2202490T3 (es) 2004-04-01
IN186768B (de) 2001-11-03
TNSN96169A1 (fr) 2005-03-15
EP0876362A1 (de) 1998-11-11
UA48205C2 (uk) 2002-08-15
AU712597B2 (en) 1999-11-11
CZ196198A3 (cs) 1998-09-16
CO4520184A1 (es) 1997-10-15
AU1180997A (en) 1997-07-17
NZ324337A (en) 2000-03-27
SK85398A3 (en) 1998-11-04

Similar Documents

Publication Publication Date Title
DE69630145D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE188471T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
ATE164843T1 (de) Naphthalinderivate, ihre herstellungsverfahren und zwischenprodukte dafür, und diese enthaltende pharmazeutische zusammensetzungen
ATE239703T1 (de) Azetidinderivate, deren herstellung und sie enthaltende arzneimittel
DE69806831D1 (de) Dithiolan Derivate, deren Herstellung und deren Heileffekt
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE193533T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE59907961D1 (de) Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
ATE297935T1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
DE69815094D1 (de) 2-(iminoethyl)-aminophenyl - derivate, deren herstellung, deren verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ATE222897T1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen,die sie enthalten
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DE59814412D1 (de) Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE69610085D1 (de) Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE204266T1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung
DE3578597D1 (de) 4-phenylphthalazin-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
NO975680D0 (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
BR9607433A (pt) Composição farmacêutica para administração parental
ATE290543T1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC